Connect with us

Technology

FinnGen Selects Azenta to Propel Personalized Medicine for Population Health Study

Published

on

Azenta will provide proteomics technology profiling on up to 20,000 individuals.

BURLINGTON, Mass., July 22, 2024 /PRNewswire/ — Azenta, Inc. (Nasdaq: AZTA) today announced its participation in the FinnGen project, a large-scale research initiative at the forefront of personalized medicine in Finland. The FinnGen project is a pioneering endeavor that has collected and is currently analyzing genomic and health data from a cohort of 500,000 Finnish biobank participants.

In collaboration with the University of Helsinki, the organization leading the FinnGen study, Azenta will provide comprehensive proteomics profiling on up to 20,000 individuals, underscoring Azenta’s commitment to advancing healthcare innovation and personalized treatments. Azenta will use Olink’s advanced proteomics technology, based on the proprietary Proximity Extension Assay, to provide high-quality protein-level measurements across all major biological pathways.

“FinnGen’s adoption of proteomics marks a pivotal advancement in our quest to decode the complexities of human health and disease. By integrating the dynamic insights of proteomics with our extensive genomic data, we can gain a deeper understanding of disease mechanisms, identify new biomarkers for early detection, and uncover novel therapeutic targets. We are pleased to collaborate with Azenta Life Sciences, and trust that they will provide excellent service and deliver high-quality proteomic data with a fast turnaround time,” said Professor Aarno Palotie, FinnGen Scientific Director from the Institute for Molecular Medicine Finland (FIMM), University of Helsinki. “Combined with excellent quality and reliable results, Azenta Life Sciences can help us construct a strong foundation for advancing the field of personalized medicine.”

“As one of the collaborators in the FinnGen Project, Azenta looks forward to making meaningful contributions to personalized medicine and revolutionizing healthcare for generations to come,” said Ginger Zhou, PhD., Senior Vice President and General Manager, GENEWIZ Multiomics & Synthesis Solutions from Azenta Life Sciences. “Multiomics technologies from Azenta enable researchers to efficiently generate detailed proteomics data from study participants carrying medically and clinically significant genetic variants, opening up a world of possibilities for understanding disease mechanisms and developing targeted treatments.”

About FinnGen

FinnGen is a large public-private partnership aiming to collect and analyze genome and health data from 500,000 Finnish biobank participants. FinnGen aims on one hand to provide novel medically and therapeutically relevant insights but also construct a world-class resource that can be applied for future studies.

FinnGen is one of the very first personalized medicine projects at this scale and the public-private collaborative nature of the project is exceptional compared to many ongoing studies. FinnGen brings together Finnish universities, hospitals and hospital districts, THL, Blood Service, biobanks, FINBB and international pharmaceutical companies and hundreds of thousands of Finns. Because collaboration is the key to achieving breakthroughs in disease prevention, diagnosis, and treatment, we welcome everyone on this journey into our shared heritage.

For more information, please visit https://www.finngen.fi/en.

About Azenta Life Sciences

Azenta, Inc. (Nasdaq: AZTA) is a leading provider of life sciences solutions worldwide, enabling impactful breakthroughs and therapies to market faster. Azenta provides a full suite of reliable cold-chain sample management solutions and multiomics services across areas such as drug development, clinical research, and advanced cell therapies for the industry’s top pharmaceutical, biotech, academic, and healthcare institutions globally. Our global team delivers and supports these products and services through our industry-leading brands, including GENEWIZ, FluidX, Ziath, 4titude, Limfinity, Freezer Pro, Barkey and B Medical Systems.

Azenta is headquartered in Burlington, Massachusetts, with operations in North America, Europe and Asia. For more information, please visit www.azenta.com.

“Safe Harbor Statement” under Section 21E of the Securities Exchange Act of 1934

Some statements in this release are forward-looking statements made under Section 21E of the Securities Exchange Act of 1934. These statements are neither promises nor guarantees but involve risks and uncertainties, both known and unknown, that could cause Azenta’s financial and business results to differ materially from our expectations. They are based on the facts known to management at the time they are made. Other forward-looking statements include but are not limited to statements about the prospects of the FinnGen Project and our ability to contribute to the advancement of personalized medicine. Factors that could cause results to differ from our expectations include the following: changes in technology and/or science that impact our ability to enable researchers to generate the proteomics data required to understand disease and develop targeted treatments and other factors and other risks, including those that we have described in our filings with the Securities and Exchange Commission, including but not limited to our Annual Report on Form 10-K, Current Reports on Form 8-K and our Quarterly Reports on Form 10-Q. As a result, we can provide no assurance that our future results will not be materially different from those projected. Azenta expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any such statement to reflect any change in our expectations or any change in events, conditions, or circumstances on which any such statement is based. Azenta undertakes no obligation to update the information contained in this press release.

INVESTOR CONTACTS:
Yvonne Perron
Vice President, Financial Planning & Analysis, and Investor Relations
ir@azenta.com

Sherry Dinsmore
sherry.dinsmore@azenta.com

Azenta’s use of third-party trademarks and brands are for identification only and does not imply affiliation or endorsement. All trademarks used herein are the property of their respective owners.

View original content to download multimedia:https://www.prnewswire.com/news-releases/finngen-selects-azenta-to-propel-personalized-medicine-for-population-health-study-302203113.html

SOURCE Azenta

Continue Reading

Technology

How Can Humanity Become Friends with the Ocean?

Published

on

By

BEIJING, Nov. 6, 2026 /PRNewswire/ — A news report from China.org.cn on China’s efforts in marine ecological governance:

“Look, white dolphins!” Such excited cries can often be heard along the coast of Xiamen, a city in east China’s Fujian Province.

The Indo-Pacific humpback dolphin, commonly known as the Chinese white dolphin, is considered Class I nationally protected wildlife in China. As apex predators in coastal waters, these dolphins are regarded as a barometer of marine ecosystem health. Back in the 1990s, however, rising shipping activity, coastal reclamation and near‑shore development severely encroached on their habitats.

To minimize disturbances to dolphin habitats, Xiamen established China’s first provincial‑level nature reserve dedicated to Chinese white dolphins in 1997. Since then, the city has continuously refined its coastal governance approaches, restricted activities with significant environmental impacts, and promoted cross‑regional collaboration in conservation. Many other ocean‑friendly initiatives have also been rolled out. These include restoring mangrove wetland ecosystems; implementing an “offshore sanitation” mechanism and organizing public beach‑clean‑up campaigns to regularly remove floating marine debris; and releasing nearly 8 billion aquatic animals across 18 species through stock enhancement programs. As a result, populations of several fish species, such as the wild large yellow croaker and yellowfin seabream, have returned to Xiamen Bay.

Recently, “AI bodyguards” have joined the conservation effort. High‑definition cameras, drones and intelligent recognition systems track dolphin activity round‑the‑clock. Automatic alerts are issued whenever vessels approach the dolphins in violation of regulations. Researchers have also created individual digital profiles for each dolphin, identifying them by their dorsal‑fin shapes and body spot patterns, while recording their movement trajectories.

Xiamen is a microcosm of China’s efforts in marine ecological governance — forging ahead boldly yet never walking alone.

Over the decades, China has taken a series of concrete steps: from founding its first marine nature reserve in 1963, to proposing the goal of “building a strong maritime nation,” and publishing the white paper “Marine Eco‑Environmental Protection in China”; from drawing marine ecological protection red lines, to actively engaging with the UN Decade of Ocean Science for Sustainable Development and signing major international agreements on marine conservation, including the UN Agreement on Biodiversity Beyond National Jurisdiction (UN BBNJ).

For decades, China has been answering a vital question through concrete action: how can humanity coexist harmoniously with the ocean and create mutual benefits?

The answer is becoming increasingly clearer. Today, China’s extensive coastline features clean waters and pristine beaches, with fish swimming freely and seabirds soaring overhead. Not long ago, China’s Blue Bay Restoration Initiative was named a UN World Restoration Flagship. Now, the 21st Xiamen World Ocean Week is officially inaugurated, bringing together experts, scholars and representatives from various countries and international organizations to discuss marine conservation and harmonious coexistence between humanity and the ocean. In marine ecological protection and governance, China is not only a proactive participant and practitioner, but also a contributor to sharing experience and shaping future approaches.

Along Xiamen’s shoreline, the sea breeze blows gently as children run after the waves, echoing the ongoing story of humanity and the ocean.

China Mosaic
http://www.china.org.cn/video/node_7230027.htm

View original content to download multimedia:https://www.prnewswire.com/news-releases/how-can-humanity-become-friends-with-the-ocean-302932059.html

SOURCE China.org.cn

Continue Reading

Technology

OneStream Surpasses 600 EMEA Customers and Triples AI Adoption

Published

on

By

OneStream triples AI customer base and deepens investment across EMEA as Founder and CEO Tom Shea presents governed Finance AI framework at Web Summit

LISBON, Portugal, Nov. 6, 2026 /PRNewswire/ — OneStream, the AI operating system for modern Finance that unifies core financial and operational processes, embedding the governance, context, and control required to make AI work for Finance, today announced it has surpassed 600 customers in EMEA and more than tripled its Finance AI customers in the region since the end of 2025. The news comes as Founder and CEO Tom Shea takes the stage at Europe’s biggest tech event, Web Summit 2026, to detail a framework for auditable, contextualized AI for Finance.

“CFOs across Europe are realizing the real advantage of AI isn’t the smartest model – it’s AI operating within a strict framework of financial governance,” said Tom Shea, Founder and CEO at OneStream. “AI is the reasoning engine, but enterprise software must be the trust engine. Our acceleration in EMEA proves leaders want a financial control tower that delivers answers they can act on without operational risk. We will continue investing heavily in the local teams and partners helping them build this secure foundation.”

Accelerating EMEA Momentum
Over the past 12 months, OneStream helped more than 100 new EMEA customers modernize their tech stack and passed 600 customers in the region, with customers in more than 35 markets. Customers span industries including manufacturing, retail, banking and financial services, pharmaceuticals, and oil and gas. Notable EMEA customers include Grupo ACS, Delivery Hero, and Swatch.

Customers across the region are using OneStream to modernize core Finance processes, replacing fragmented legacy systems with a unified platform for financial close, consolidation, reporting, and planning. This unified foundation helps teams keep pace with complex regulatory requirements across EMEA, while providing the governed data necessary to leverage AI for accelerated insights and real business value.

OneStream’s Finance AI adoption is growing alongside its broader platform growth. The number of EMEA customers using OneStream’s Finance AI has more than tripled since the end of 2025.

To support this sustained regional acceleration, OneStream continues to scale its operations and partner ecosystem, building on its established regional presence across London, Manchester, Paris, Amsterdam, and Madrid.

“Finance leaders across EMEA are modernizing their core Finance platforms to keep pace with complex regulation and move faster,” said Matt Rodgers, EVP, EMEA at OneStream. “That modernization is what enables them to take AI from pilots to enterprise-wide deployment, because it gives them a data foundation they can actually trust. Our momentum in the region underscores a fundamental shift toward governed, unified enterprise platforms that deliver real business value.”

Building Trust in AI Agents

Shea will appear in a featured fireside chat titled “Why AI and SaaS Need Each Other” on Thursday, Nov. 12, at 1:25 PM on Stage 7. Moderated by Hope King, Founder of Macro Talk, and featuring Luminance CEO Eleanor Lightbody, the session will examine the evolving role of enterprise software as AI agents take on increasingly complex workflows. Shea will detail how governed data, strict access controls, and transparent audit trails determine how safely organizations can let autonomous agents act on their own.

To learn more about Shea’s session at Web Summit, click here.

About OneStream

OneStream is the AI operating system for modern Finance that unifies core financial close, planning, and operational processes and data, in one intelligent platform, all embedded with the governance, context, and control required to make AI work for Finance.

With over 1,900 customers, including 16% of the Fortune 500, a strong ecosystem of go-to-market, implementation, and development partners and 1,600 employees, we empower the Office of the CFO to become a critical driver of business strategy and execution. To learn more, visit onestream.com.

Media Contact

Jaclyn Proctor
Media Relations Contact
OneStream
media@onestreamsoftware.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/onestream-surpasses-600-emea-customers-and-triples-ai-adoption-302931403.html

SOURCE OneStream, Inc.

Continue Reading

Technology

Insilico Open-Sources 24/7 Personal Longevity Superintelligence to Turn Quantified-Self Data into Predictive Health States and Aging Research

Published

on

By

CAMBRIDGE, Mass., Nov. 6, 2026 /PRNewswire/ — Insilico Medicine, a clinical-stage generative AI drug discovery company, today announced the open-source release of Longevity Grok, the Personal Longevity Superintelligence (PLSI) and launched the website longevitygrok.si, in collaboration with leading geroscience researcher David Sinclair from Harvard Medical School. Developed for the Grok Bot platform, PLSI is an open-source, multi-agent AI system designed to unify fragmented personal health records, track biological analysis, formulate personalized lifestyle interventions, predict and score post-intervention biomarker changes, as well as drive communal AI-powered geroscience research.

For decades, health management and longevity medicine have been hampered by severe data fragmentation. Laboratory blood panels, continuous glucose monitoring, wearable streams, epigenetic assays, and clinical records sit across disconnected portals, leaving patients unable to follow their biological trajectory and clinicians working from incomplete histories. Modern healthcare turns to LLMs to close that gap, however, without persistent, auditable memory or follow-up on if advice actually improves outcomes, they rarely outperform traditional methods.

Personal Longevity Superintelligence (PLSI) addresses this gap with a continuous, 24/7 automated research loop. It converts fragmented medical data into a standardized longitudinal health trajectory and generates accountable, predictive guidance through a multi-agent architecture. The system continuously forecasts health risks, proposes interventions, and scores outcomes through closed-loop feedback.

Running within Grok Bot’s secure environment, it coordinates a team of up to 30 specialized AI agents, standardizes heterogeneous records with clinical coding systems such as LOINC, RxNorm, and UCUM, and uses always-on routines to monitor longevity science updates, organize incoming data, and keep the personal health state current without constant re-prompting. The same system is framed for three complementary roles:

As a personal longevity assistant, PLSI turns scattered labs, wearables, epigenetic assays, and clinical files into a unified, audit-ready health trajectory on the user’s device. It proposes lifestyle, nutritional, or longevity interventions with an auditable “prediction card” (target biomarker, confidence interval, time horizon, and evidence grade), evaluates each plan through an agent-driven adversarial review. When follow-up results arrive, PLSI scores whether outcomes fall within the predicted interval, confirms direction, and tracks calibration over time, turning each choice into a checkable N-of-1 experiment. Users can also voluntarily allocate unused daily token quota to Idle Research in the background to find new ways to increase their lifespan.

As a physician’s assistant, PLSI supplies structured longitudinal context instead of fragmented PDFs and portal exports. Standardized representations and a coherent biological trajectory help clinicians better organize their workflow Prediction cards and evidence grades aid in decision-making, while closed-loop scoring after follow-up supports auditable discussion of response and adherence. PLSI also features safeguards that overrule AI discretion to keep  formal diagnosis and prescriptions solely with licensed physicians.

As a partner for aging research, PLSI extends individual tracking into communal discovery. Users may opt in to contribute consented, deidentified trajectories to Longevity Mothership via an anonymous relay with an irrevocable kill switch to purge records on demand. Idle Research is a modern take on volunteer computing platforms , such as Folding@home, which let autonomous researcher agents scan literature, formulate hypotheses, and design analyses based on  public databases to accelerate target discovery and other anti-aging discovery activities.

Across all three roles, privacy is the default: a zero-trust architecture keeps raw medical files and identifiable clinical records in the user’s environment , unless the user explicitly opts into communal research. Both the PLSI Client and the Longevity Mothership backends are fully open-source and freely available on GitHub for review and contribution. Both setups feature data controller agents, which scrub the data at egress and intake points to prevent entry re-identification.

PLSI is available to all Grok Bot users and can be installed by instructing your bot with the following one-liner:

Set yourself up using https://github.com/Insilico-org/plsi 

The agentic skills and code are provided as an open-source package which can be inspected and modified by all, according to their needs.

“Longevity Grok turns Grok Bot into an open platform where individuals, physicians, and scientists can use AI to better understand their health, predict the effects of interventions, and find ways to live longer, healthier lives,” said David A. Sinclair, Ph.D., Professor of Genetics and Co-Director of the Paul F. Glenn Center for Biology of Aging Research at Harvard Medical School. “What makes this exciting is that people can contribute to scientific discovery while improving their own health, helping us understand why we age and how we might slow or even reverse it.”

“Currently, there are zero tools that are clinically proven to give a healthy person an additional year of life if they are already dieting, exercising, sleeping, and getting regular diagnostics,” said Alex Zhavoronkov, Ph.D., founder and CEO of Insilico Medicine. “Longevity Grok is a distributed system designed around a personal research space where you can work with your own data to optimize your health, longevity, and peak-span trajectories. As this system diffuses into the community, we expect to achieve longevity superintelligence, enabling a vast network of individuals to conduct autonomous research on their own biology while utilizing shared computation resources to pursue advanced longevity experiments. Aging is the only inescapable constraint on human freedom, and pushing this frontier is about giving people the optionality to remain young, healthy, and productive for as long as possible.”

Longevity has been central to Insilico’s mission since its inception. The company’s path drew industry attention in 2015 at the NVIDIA GTC conference, where Alex Zhavoronkov, Ph.D., founder and CEO of Insilico, challenged the tech world with a provocative question: “Can NVIDIA cure aging?” In 2014, Insilico established the annual Aging Research and Drug Discovery (ARDD) meeting, now widely regarded as a leading academic gathering for geroscience and biogerontology. The 13th ARDD, held at Harvard University in 2026, brought together leading academic investigators, pharmaceutical executives, and clinical pioneers to translate longevity discoveries into actionable medicine.

In 2026, Insilico accelerated the translation of AI-driven longevity research from experimental theory to transformative biological interventions. In April, the company announced the industry’s first longevity board of high-profile scientists, chaired by Andrew Adams, Ph.D., Group Vice President of Molecular Discovery at Eli Lilly and Company, to advance AI-driven aging research for drug discovery. In September, Insilico open-sourced an AI longevity toolkit, including LongevityBench, Longevity-LLMs, and LongevityClaw, with collaborators in a Cell cover study, accelerating research and therapeutic development. That publication follows Insilico’s contemporaneous Nature Biotechnology paper, in which Rentosertib, the company’s most advanced AI-driven pipeline candidate, showed biological age reversal according to Phase IIa clinical data across six independent proteomic aging clocks.

Since 2014, Insilico has published more than 50 research papers on aging and longevity, aging biomarkers, therapeutic targets, and therapeutics implicated in aging, longevity, and disease.

About Insilico Medicine

Insilico Medicine is a pioneering global biotechnology company dedicated to integrating artificial intelligence and automation technologies to accelerate drug discovery, drive innovation in the life sciences, and extend healthy longevity to people on the planet. The company was listed on the Main Board of the Hong Kong Stock Exchange on December 30, 2025, under the stock code 03696.HK.

By integrating AI and automation technologies and deep in-house drug discovery capabilities, Insilico is delivering innovative drug solutions for unmet needs including fibrosis, oncology, immunology, pain, and obesity and metabolic disorders. Additionally, Insilico extends the reach of Pharma. AI across diverse industries, such as advanced materials, agriculture, nutritional products and veterinary medicine.

For more information, please visit www.insilico.com

View original content:https://www.prnewswire.com/news-releases/insilico-open-sources-247-personal-longevity-superintelligence-to-turn-quantified-self-data-into-predictive-health-states-and-aging-research-302931941.html

SOURCE Insilico Medicine

Continue Reading

Trending